U.S. court issues decision in Trintellix patent litigation upholding active ingredient patent
Valby, Denmark, 1 October 2021 - H. Lundbeck A/S (Lundbeck) announces that the U.S. District Court for the District of Delaware (the ‘Court’) has issued its decision upholding the validity of Lundbeck’s patent covering the active ingredient in Trintellix, vortioxetine (U.S. Patent No. 7,144,884) in patent litigation proceedings against six generic manufacturers challenging Lundbeck’s patent rights to Trintellix (vortioxetine) in the U.S. Lundbeck and its partner, Takeda Pharmaceutical Company Limited (Takeda), filed the infringement actions against the six generic manufacturers Alembic,